1. A novel antibody–drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity. (2nd January 2016) Authors: Jiang, Linlin; Yang, Ming; Zhang, Xiaoyun; Bao, Shiqi; Ma, Li; Fan, Dongmei; Zhou, Yuan; Xiong, Dongsheng; Zhen, Yongsu Journal: Journal of drug targeting Issue: Volume 24:Number 1(2016) Page Start: 47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A novel enediyne‐integrated antibody–drug conjugate shows promising antitumor efficacy against CD30+ lymphomas. Issue 3 (26th January 2018) Authors: Wang, Rong; Li, Liang; Zhang, Shenghua; Li, Yi; Wang, Xiaofei; Miao, Qingfang; Zhen, Yongsu Journal: Molecular oncology Issue: Volume 12:Issue 3(2018) Page Start: 339 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer. (31st December 2022) Authors: He, Shiming; Zhao, Chunyan; Tao, Hongyu; Sheng, Weijin; Gao, Ruijuan; Liu, Xiujun; Zhen, Yongsu Journal: Drug delivery Issue: Volume 29:Number 1(2022) Page Start: 1243 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Albumin‐Mediated Delivery of Bioactive Peptides for Pancreatic Cancer Therapy. Issue 7 (29th April 2020) Authors: Du, Yue; Shang, Boyang; Yi, Hongfei; Yuan, Yongliang; Zhen, Yongsu; Xu, Jian Journal: Advanced therapeutics Issue: Volume 3:Issue 7(2020) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Construction of a genetically engineered chimeric apoprotein consisting of sequences derived from lidamycin and neocarzinostatin. Issue 1 (January 2016) Authors: Jiang, Wenguo; Shang, Boyang; Li, Liang; Zhang, Shenghua; Zhen, Yongsu Journal: Anti-cancer drugs Issue: Volume 27:Issue 1(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma. (28th April 2019) Authors: Wang, Rong; Li, Liang; Duan, Aijun; Li, Yi; Liu, Xiujun; Miao, Qingfang; Gong, Jianhua; Zhen, Yongsu Journal: Cancer letters Issue: Volume 448(2019) Page Start: 84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Lidamycin inhibits tumor initiating cells of hepatocellular carcinoma Huh7 through GSK3β/β‐catenin pathway. Issue 1 (16th July 2013) Authors: Chen, Yi; Yu, Dongke; Zhang, Caixia; Shang, Boyang; He, Hongwei; Chen, Jinjing; Zhang, Hao; Zhao, Wuli; Wang, Zhen; Xu, Xiaoyu; Zhen, Yongsu; Shao, Rong‐guang Journal: Molecular carcinogenesis Issue: Volume 54:Issue 1(2015:Jan.) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Lidamycin inhibits tumor initiating cells of hepatocellular carcinoma Huh7 through GSK3β/β‐catenin pathway. Issue 1 (16th July 2013) Authors: Chen, Yi; Yu, Dongke; Zhang, Caixia; Shang, Boyang; He, Hongwei; Chen, Jinjing; Zhang, Hao; Zhao, Wuli; Wang, Zhen; Xu, Xiaoyu; Zhen, Yongsu; Shao, Rong‐guang Journal: Molecular carcinogenesis Issue: Volume 54:Issue 1(2015:Jan.) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗